The companies have received final approval from the US Food and Drug Administration (USFDA) for their abbreviated new drug applications for Valsartan tablets USP in multiple strengths of 40 mg, 80 mg, 160 mg and 320 mg, domestic firms said in separate statements.
Three domestic firms, Aurobindo Pharma , Lupin and Jubilant Life Sciences , have received final
approval from US health regulator to sell generic copies of Valsartan tablets used for treatment of hypertension.
The current annualised US market size for Valsartan tablets USP, 40 mg, 80 mg, 160 mg, and 320 mg as per IMS is around USD 2 billion, the pharma firms said. While Lupin has launched the product in the US market already, Jubilant Life Sciences said it planned to launch the drug immediately. Aurobindo Pharma also said the product is ready for launch.
The companies have received final approval from the US Food and Drug Administration (USFDA) for their abbreviated new drug applications for Valsartan tablets USP in multiple strengths of 40 mg, 80 mg, 160 mg and 320 mg, domestic firms said in separate statements.
The tablets are indicated for treatment of hypertension and are the generic versions of Novartis Pharmaceuticals Corporation's Diovan tablets. Shares of Aurobindo Pharma closed down by 3.69 percent at Rs 1,088.30, while Lupin fell 2.46 per cent to Rs 1,394.55 at close. Jubilant Life Sciences, however, closed higher by 3.69 percent at Rs 144.85.
Aurobindo Pharm stock price
On January 06, 2015, Aurobindo Pharma closed at Rs 1088.30, down Rs 41.7, or 3.69 percent. The 52-week high of the share was Rs 1171.20 and the 52-week low was Rs 375.00.
The company's trailing 12-month (TTM) EPS was at Rs 56.06 per share as per the quarter ended September 2014. The stock's price-to-earnings (P/E) ratio was 19.41. The latest book value of the company is Rs 137.66 per share. At current value, the price-to-book value of the company is 7.91.
Anda sedang membaca artikel tentang
Aurobindo, Jubilant get USFDA nod for hypertension drug
Dengan url
http://kebugaranhidup.blogspot.com/2015/01/aurobindo-jubilant-get-usfda-nod-for.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Aurobindo, Jubilant get USFDA nod for hypertension drug
namun jangan lupa untuk meletakkan link
Aurobindo, Jubilant get USFDA nod for hypertension drug
sebagai sumbernya
0 komentar:
Posting Komentar